Physician extenders for cost-effective management of hypercholesterolemia

Journal of General Internal Medicine

Volumn 11, Issue 5, 1996, Pages 277-286

  Schectman, Gordon ^a,c   Wolff, Nancy ^b   Byrd, James C ^a   Hiatt, Janet G ^a   Hartz, Arthur ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c Div of General Internal Medicine   (United States)

Author keywords

bile acid sequestrants; hypercholesterolemia; lovastatin; nicotinic acid; physician extenders

Indexed keywords

MEVINOLIN;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CORONARY RISK; COST EFFECTIVENESS ANALYSIS; DIETARY INTAKE; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY;

EID: 0029994805     PISSN: 08848734     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02598268     Document Type: Article

References (32)

1. The Scandinavian Simvastatin Survival Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-9.
2. Jukema J, Bruschke A, Boven AV, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995;91:2528-40.
3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol Levels. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-21.
4. Sempos C, et al. Prevalence of high blood cholesterol among US adults: an update based on guidelines from the second report of the National Cholesterol Education Program Adult Treatment Panel. JAMA. 1993;269:3009-14.
5. Goldman L, Gordon D, Rifkind B, et al. Cost and health implications of cholesterol lowering. Circulation. 1992;85:1960-8.
6. Cohen MV, Byrne MJ, Levine B, Gutowski T, Adelson R. Low rate of treatment of hypercholesterolemia by cardiologists in patients with suspected and proven coronary artery disease. Circulation. 1991;83:1294-304.
7. Superko HR, Desmond DA. de SV, Vranizan KM, Farquhar JW. Blood cholesterol treatment attitudes of community physicians: a major problem. Am Heart J. 1988;116:849-55.
8. Schectman J, Elinsky E, Bartman B. Primary care clinician compliance with cholesterol treatment guidelines. J Gen Intern Med. 1991;6:121-5.
9. Hyman D, Maibach E, Flora J, Fortmann S. Cholesterol treatment practices of primary care physicians. Public Health Rep. 1992; 107:441-8.
10. Blair T, Bryant F, Bocuzzi S. Treatment of hypercholesterolemia by a clinical nurse using a stepped-care protocol in a nonvolunteer population. Arch Intern Med. 1988;148:1046-8.
11. Debusk R, Miller N, Superko H, et al. A case-management system for coronary risk factor modification after acute myocardial infarction. Ann Intern Med. 1994;120:721-9.
12. Shaffer J, Wexler L. Reducing low-density lipoprotein cholesterol levels in an ambulatory care system. Arch Intern Med. 1995; 155:2330-5.
13. Schectman G, Hiatt J, Hartz A. Telephone contacts do not improve compliance to niacin or bile acid sequestrants. Ann Pharmacother. 1994;28:29-34.
14. The Expert Panel. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med. 1988;148:36-69.
15. Kinosian B, Glick H, Garland G. Cholesterol and coronary heart disease: predicting risks by levels and ratios. Ann Intern Med. 1994;121:641-7.
16. Assmann G, Schulte H, Funke H, Eckardstein A, Seedorf U. The prospective cardiovascular Munster (PROCAM) study: identification of high-risk individuals for myocardial infarction and the role of high-density lipoprotein. In: Miller N, ed. High Density Lipoproteins and Atherosclerosis II. Amsterdam: Excerpta Medica;1989; ICS 826:51-6.
17. Allain C, Poon L, Chan C, Richmond W, Fu P. Enzymatic determination of total serum cholesterol. Clin Chem. 1974;20:470-5.
18. Megraw R, Dunn D, Biggs H. Manual and continuous-flow colorimetry of triacylglycerols by a fully enzymic method. Clin Chem. 1979;25:273-8.
19. 2. Clin Chem. 1983;29:2026-30.
20. Friedewald W, Levy R, Fredrickson D. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without the use of the preparative centrifuge. Clin Chem. 1972;18:499-502.
21. Rothman K. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1:43-6.
22. Giles W, Anda R, Jones D, Serdula M, Merritt R, DeStefano F. Recent trends in the identification and treatment of high blood cholesterol by physicians. Progress and missed opportunities. JAMA. 1993;269:1133-8.
23. Fix KN, Oberman A. Barriers to following National Cholesterol Educational Program guidelines. An appraisal of poor physician compliance [editorial; comment]. Arch Intern Med. 1992;152:2385-7.
24. Maiman L, Greenland P. Patterns of physicians' treatments for referral patients from public cholesterol screening. Am J Prev Med. 1991;7:273-9.
25. Hunninghake D, Stein E, Dujovne C, et al. The efficacy of intensive dietary therapy alone or combined with lovastatin in outpatients with hypercholesterolemia. N Engl J Med. 1993;328: 1213-9.
26. Henkin Y, Garber D, Osterlund L, Darnell B. Saturated fats, cholesterol, and dietary compliance. Arch Intern Med. 1992;152:1167-74.
27. Illingworth D, Stein W, Mitchel Y, et al. Comparative effects of lovastatin and niacin in primary hypercholesterolemia: a prospective trial. Arch Intern Med. 1994;154:1586-95.
28. Schectman G, Hiatt J, Hartz A. Evaluation of the effectiveness of lipid-lowering therapy (bile acid sequestrants, niacin, psyllium and lovastatin) for treating hypercholesterolemia in veterans. Am J Cardiol. 1993;71:759-65.
29. Andrade S, Walker A, Gottlieb L, et al. Discontinuation of antihyperlipidemic drugs. Do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med. 1995;332:1125-31.
30. Heudebert G, Ruiswyk JV, Hiatt J, Schectman G. Combination drug therapy for hypercholesterolemia: the trade-off between cost and simplicity. Arch Intern Med. 1993;153:1828-37.
31. The Lipid Research Clinics Program. The Lipid Research Clinics Primary Prevention Trial results. I: reduction in the incidence of coronary heart disease. JAMA. 1984;251:351-64.
32. Shear C, Franklin F, Stinnett S, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. Effect of patient characteristics on lovastatin-indnced changes in plasma concentrations of lipids and lipoproteins. Circulation. 1992;85:1293-303.